A Phase 2 trial of MYK-461 in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

Trial Profile

A Phase 2 trial of MYK-461 in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EXPLORER-HCM
  • Sponsors MyoKardia
  • Most Recent Events

    • 07 Aug 2017 according to a MyoKardia media release, company look forward to discussing with FDA the potential for this study to serve as a pivotal study.
    • 07 Aug 2017 Planned number of patients changed from 100 to 250, according to a MyoKardia media release.
    • 07 Aug 2017 According to a MyoKardia media release, this study is expected to initiate by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top